Thuốc Quinidine Sulfate

0
171
Thuốc Quinidine Sulfate
Thuốc Quinidine Sulfate

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

    106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

    107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

    108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

    AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

    † Use is not currently included in the labeling approved by the US Food and Drug Administration.

    References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

109. Suntharasamai P, Vanijanond S, Harinasuta T et al. A double-blind randomised trial of quinine vs quinidine in chloroquine resistant falciparum malaria. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (June 22):15. Abstract.

110. Bunnag D, Suntharasamai P, Charoenlarp P et al. Double blind randomised study of quinidine and quinidine slow release on chloroquine resistant falciparum malaria. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (June 22):19. Abstract.

111. Centers for Disease Control. Notice of claimed investigational exemption for a new drug (Quinidine Gluconate Injection USP). FD Form 1571. Atlanta, GA; 1985.

112. Harinasuta T, Bunnag D, Chindanonda D. Drug-resistant plasmodium falciparum in thailand. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (Jun 22):9. Abstract.

113. West SG, McMahon M, Portanova JP. Quinidine-induced lupus erythematosus. Ann Intern Med. 1984; 100:840-2. http://www.ncbi.nlm.nih.gov/pubmed/6372564?dopt=AbstractPlus

114. Lavie CJ, Biundo J, Quinet RJ et al. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med. 1985; 145:446-8. http://www.ncbi.nlm.nih.gov/pubmed/3977514?dopt=AbstractPlus

116. Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus verapamil: possible additive competition at alpha-adrenergic receptors. N Engl J Med. 1985; 312:167-70. http://www.ncbi.nlm.nih.gov/pubmed/2981405?dopt=AbstractPlus

117. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981; 64:437-41. http://www.ncbi.nlm.nih.gov/pubmed/7196300?dopt=AbstractPlus

118. Ochs HR, Jancik B, Kumm D. Atrial fibrillation: effect of diltiazem and verapamil, with and without quinidine. Clin Pharmacol Ther. 1984; 35:264.

119. Lilly USA. Quinidine gluconate injection prescribing information. Indianapolis, IN; 2012 Feb 24.

120. Bar-El Y, Shimoni Z, Flatau E. Quinidine-induced lupus erythematosus. Am Heart J. 1986; 111:1209-10. http://www.ncbi.nlm.nih.gov/pubmed/3487241?dopt=AbstractPlus

121. Phillips RE, Looareesuwan S, White NJ et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. BMJ. 1986; 292:1319-21. http://www.ncbi.nlm.nih.gov/pubmed/3085830?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1340320&blobtype=pdf

122. Rudnitsky G, Miller KD, Padva T et al. Continuous-infusion quinidine gluconate for treating children with severe Plasmodium falciparum malaria. J Infect Dis. 1987; 155:1040-3. http://www.ncbi.nlm.nih.gov/pubmed/3549916?dopt=AbstractPlus

123. Malaria Branch, US Centers for Disease Control, Atlanta, GA: Personal communication.

124. Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med. 1989; 321:65-70. http://www.ncbi.nlm.nih.gov/pubmed/2659994?dopt=AbstractPlus

125. Anon. Treatment of severe Plasmodium falciparum malaria with quinidine gluconate: discontinuation of parenteral quinine from CDC drug service. MMWR Morb Mortal Wkly Rep. 1991; 40:240. http://www.ncbi.nlm.nih.gov/pubmed/1848916?dopt=AbstractPlus

126. Anon. Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC drug service. MMWR Recomm Rep. 1991; 40(RR-4):21-3. http://www.ncbi.nlm.nih.gov/pubmed/1850497?dopt=AbstractPlus

128. White NJ, Plorde JJ. Malaria. In: Wilson JD, Braunwald E, Isselbacher et al, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw Hill, Inc; 1991:782-8.

129. Van Lith RM, Appleby DH. Quinidine-nifedipine interaction. Drug Intell Clin Pharm. 1985; 19:829-31. http://www.ncbi.nlm.nih.gov/pubmed/4064916?dopt=AbstractPlus

130. World Health Organization Division of Control of Tropical Diseases. Severe and complicated malaria. Trans R Soc Trop Med Hyg. 1990; 84(Suppl 2):1-65.

131. Verapamil/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:759.

132. Nifedipine/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:606.

133. Procainamide/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:596.

134. Anon. Drugs for parasitic infections. Treat Guidel Med Lett. 2010; 8:e1-16. http://www.medletter.com

135. Farringer JA, McWay-Hess K, Clementi WA. Cimetidine–quinidine interaction. Clin Pharm. 1984; 3:81-3. http://www.ncbi.nlm.nih.gov/pubmed/6697678?dopt=AbstractPlus

136. Green JA, Clementi WA, Porter C et al. Nifedipine–quinidine interaction. Clin Pharm. 1983; 2:461-5. http://www.ncbi.nlm.nih.gov/pubmed/6627876?dopt=AbstractPlus

137. Munger MA, Jarvis RC, Nair R et al. Elucidation of the nifedipine–quinidine interaction. Clin Pharmacol Ther. 1989; 45:411-6. http://www.ncbi.nlm.nih.gov/pubmed/2702799?dopt=AbstractPlus

138. Hughes B, Dyer JE, Schwartz AB. Increased procainamide plasma concentrations caused by quinidine: a new drug interaction. Am Heart J. 1987; 114:908-9. http://www.ncbi.nlm.nih.gov/pubmed/3661379?dopt=AbstractPlus

139. Farringer JA, Green JA, O’Rourke RA et al. Nifedipine-induced alterations in serum quinidine concentrations. Am Heart J. 1984; 108:1570-2. http://www.ncbi.nlm.nih.gov/pubmed/6507260?dopt=AbstractPlus

140. Cimetidine/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:604.

141. Wyler DJ. Malaria: overview and update. Clin Infect Dis. 1993; 16:449-58. http://www.ncbi.nlm.nih.gov/pubmed/8513046?dopt=AbstractPlus

142. Centers for Disease Control and Prevention. Availability of parenteral quinidine gluconate for treatment of severe or complicated malaria. MMWR Morb Mortal Wkly Rep. 1996; 45:494. http://www.ncbi.nlm.nih.gov/pubmed/8628210?dopt=AbstractPlus

143. Centers for Disease Control and Prevention. CDC treatment guidelines: Treatment of malaria (guidelines for clinicians). 2013 Jul. From the CDC website. Accessed 2013 Sep 27. http://www.cdc.gov/malaria

144. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States (based on drugs currently available for use in the United States–updated July 1, 2013). From the CDC website. Accessed 2013 Sep 27. http://www.cdc.gov/malaria

145. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation. 1991; 84:1977-83. http://www.ncbi.nlm.nih.gov/pubmed/1834365?dopt=AbstractPlus

146. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993; 270:1589-95. http://www.ncbi.nlm.nih.gov/pubmed/8371471?dopt=AbstractPlus

147. Pratt CM, Moye L. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development. J Clin Pharmacol. 1990; 30:967-74. http://www.ncbi.nlm.nih.gov/pubmed/2122983?dopt=AbstractPlus

148. Rosenthal PJ, Petersen C, Geertsma FR et al. Availability of intravenous quinidine for falciparum malaria. N Engl J Med. 1996; 235:138.

149. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation. 1990; 82:1106-16. http://www.ncbi.nlm.nih.gov/pubmed/2144796?dopt=AbstractPlus

153. Anon. Notice to readers: Availability and use of parenteral quinidine gluconate for severe or complicated malaria. MMWR Morb Mortal Wkly Rep.2000;49:1138-40.

154. Humar A, Sharma S, Zoutman D et al. Fatal falciparum malaria in Canadian travellers. CMAJ. 1997; 156:1165-7. http://www.ncbi.nlm.nih.gov/pubmed/9141989?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1227244&blobtype=pdf

156. Hansten PD, Horn JR eds. Drug Interactions. St. Louis MO: Facts and Comparisons; 2001 Apr: 673a.

157. Min DI, Ku Y, Geraets DR et al. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol. 1996; 36:469-76. http://www.ncbi.nlm.nih.gov/pubmed/8739026?dopt=AbstractPlus

159. Abbott Laboratories. Biaxin (clarithromycin) Filmtab tablets, XL Filmtab extended-release tablets, and granules for oral suspension prescribing information. North Chicago, IL; 2003 May.

161. World Health Organization (WHO). Guidelines for the treatment of malaria. 2nd edition. Geneva, Switzerland: World Health Organization; 2010. Updates may be available at WHO website. http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html

163. Teva Pharmaceuticals. Quinidine sulfate tablet, film coated, extended release prescribing information. Sellersville, PA; 2003 Jun.

164. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 18th ed. Philadelphia, PA: Elsevier Mosby: 2008.

165. Dubin A. Cardiac arrhythmias. In: Kliegman RM, Behrman RE, Jenson HB, eds. Kliegman: Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2007.

166. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. 1206-1209.

167. Watson Laboratories. Quinidine sulfate tablet USP prescribing information. Corona, CA; 2005 Jun.

168. Watson Laboratories. Quinidine gluconate tablet, extended-release prescribing information. Corona, CA; 2005 Jun.

169. Mutual Pharmaceutical. Quinidine gluconate tablet, extended-release prescribing information. Philadelphia, PA; 2004 Jan.

170. Sandoz. Quinidine sulfate tablet prescribing information. Princeton, NJ; 2008 Nov.

171. Centers for Disease Control and Prevention. Notice to readers: new medication for severe malaria available under an investigational new drug protocol. MMWR Morb Mortal Wkly Rep. 2007; 56:769-70.

172. Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States. From CDC website. Accessed 2014 Jun 2. http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html

174. Avanir Pharmaceuticals, Inc. Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules prescribing information. Aliso Viejo, CA; 2013 Dec.

300. Page RL, Joglar JA, Caldwell MA et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67:e27-e115.

301. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1-76. http://www.ncbi.nlm.nih.gov/pubmed/24685669?dopt=AbstractPlus

b. AHFS drug information 2017. McEvoy GK, ed. Quinidine Gluconate, Quinidine Quinidine Sulfate. Bethesda, MD: American Society of Health-System Pharmacists; 2017.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:998-9.

The content of Holevn is solely for the purpose of providing information about Thuốc Quinidine Sulfate  and is not intended to be a substitute for professional medical advice, diagnosis or treatment. Please contact your nearest doctor or clinic, hospital for advice. We do not accept liability if the patient arbitrarily uses the drug without following a doctor’s prescription.

    Reference from: https://www.drugs.com/monograph/quinidine-sulfate.html

  • Decreases myocardial excitability and conduction velocity, and may depress myocardial contractility.b

  • Possesses anticholinergic properties that may modify the direct myocardial effects of the drug.b

  • The exact mechanism has not been determined conclusively, but is believed to combine with fast sodium channels in their inactive state and thereby inhibit recovery after repolarization in a time- and voltage-dependent manner, which is associated with subsequent dissociation of the drug from the sodium channels.b

  • Suppresses automaticity in the His-Purkinje system.b Decreases conduction velocity in the atria, ventricles, and His-Purkinje system, and may decrease or cause no change in conduction velocity through the AV node.

  • May suppress atrial fibrillation or flutter by prolonging the effective refractory period (ERP) and increasing the action potential duration in atrial and ventricular muscle and in the His-Purkinje system.b

  • May produce sinus tachycardia via its anticholinergic effects.b

  • Has a direct negative inotropic effect, but therapeutic plasma concentrations of the drug do not usually depress contractility in the normal heart.b

  • May reduce peripheral resistance and blood pressure by blockade of α-adrenergic receptors and by its effects on myocardial contractility; decreased blood pressure is most likely to occur with high plasma concentrations of the drug.b At high plasma concentrations, quinidine may produce sinus tachycardia because of reflex sympathetic response to the drug’s hypotensive effect.b

  • When used as an antimalarial agent, acts principally as an intraerythrocytic schizonticide; the drug has little effect on sporozoites or preerythrocytic parasites.119

  • Gametocidal against Plasmodium vivax and P. malariae, but not P. falciparum.119

  • Appears to be more active (in vitro on a weight basis) than quinine against P. falciparum.102103104112

Advice to Patients

  • If used for prophylaxis against recurrence of atrial fibrillation, advise patient of the risks and benefits.163167168169170 Advise patients that the goal is reduction in frequency of episodes of atrial fibrillation (probably not elimination); symptomatic benefits may occur if reduced frequency of fibrillatory episodes is achieved; no data indicate that reduced frequency of fibrillatory episodes reduces risks of irreversible harm through stroke or death; and data are available suggesting that quinidine treatment is likely to increase the risk of death.163167168169170

  • Importance of informing clinician if rash, fever, unusual bleeding or bruising, ringing in the ears, or visual disturbance occurs.b

  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.119163167168169170

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.119163167168169170

  • Importance of informing patients of other important precautionary information.119163167168169170 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

quiNIDine Gluconate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, extended-release

324 mg (equivalent to quinidine 202 mg)*

quiNIDine Gluconate Extended-release Tablets

Parenteral

Injection

80 mg (equivalent to quinidine 50 mg) per mL*

quiNIDine Gluconate Injection

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

quiNIDine Sulfate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

200 mg (equivalent to quinidine 166 mg)*

quiNIDine Sulfate Tablets

300 mg (equivalent to quinidine 249 mg)*

quiNIDine Sulfate Tablets

Tablets, extended-release

300 mg (equivalent to quinidine 249 mg)*

quiNIDine Sulfate Extended-release Tablets

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 14, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

1. Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55:1-7. http://www.ncbi.nlm.nih.gov/pubmed/830196?dopt=AbstractPlus

2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30:287-95. http://www.ncbi.nlm.nih.gov/pubmed/3748010?dopt=AbstractPlus

100. Report of a WHO Scientific Group. Advances in malaria chemotherapy: Technical Report Series No. 711. Geneva: World Health Organization; 1984:21-33,60-85,97-8.

102. Phillips RE, Warrell DA, White NJ et al. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med. 1985; 312:1273-8. http://www.ncbi.nlm.nih.gov/pubmed/3887162?dopt=AbstractPlus

103. White NJ, Looareesuwan S, Warrell DA et al. Quinidine in falciparum malaria. Lancet. 1981; 2:1069-71. http://www.ncbi.nlm.nih.gov/pubmed/6118523?dopt=AbstractPlus

104. Agosti JM, Miller KD, Pappaioanou M et al. Plasmodium falciparum malaria and intravenous quinidine gluconate. Ann Intern Med. 1985; 103:307. http://www.ncbi.nlm.nih.gov/pubmed/3893261?dopt=AbstractPlus

105. Anon. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb Mortal Wkly Rep. 1985; 34:371. http://www.ncbi.nlm.nih.gov/pubmed/3923321?dopt=AbstractPlus

106. Ochs HR, Grube E, Greenblatt DJ et al. Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J. 1980; 99:468-75. http://www.ncbi.nlm.nih.gov/pubmed/7361649?dopt=AbstractPlus

107. Swerdlow CD, Yu JO, Jacobson E et al. Safety and efficacy of intravenous quinidine. Am J Med. 1983; 75:36-42. http://www.ncbi.nlm.nih.gov/pubmed/6859083?dopt=AbstractPlus

108. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983; 5:173-5. http://www.ncbi.nlm.nih.gov/pubmed/6188885?dopt=AbstractPlus

109. Suntharasamai P, Vanijanond S, Harinasuta T et al. A double-blind randomised trial of quinine vs quinidine in chloroquine resistant falciparum malaria. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (June 22):15. Abstract.

110. Bunnag D, Suntharasamai P, Charoenlarp P et al. Double blind randomised study of quinidine and quinidine slow release on chloroquine resistant falciparum malaria. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (June 22):19. Abstract.

111. Centers for Disease Control. Notice of claimed investigational exemption for a new drug (Quinidine Gluconate Injection USP). FD Form 1571. Atlanta, GA; 1985.

112. Harinasuta T, Bunnag D, Chindanonda D. Drug-resistant plasmodium falciparum in thailand. In: Faculty of Tropical Medicine, Hospital for Tropical Diseases, Mahidol University. Symposium on quinidine on falciparum malaria. Bangkok, Thailand: 1984; (Jun 22):9. Abstract.

113. West SG, McMahon M, Portanova JP. Quinidine-induced lupus erythematosus. Ann Intern Med. 1984; 100:840-2. http://www.ncbi.nlm.nih.gov/pubmed/6372564?dopt=AbstractPlus

114. Lavie CJ, Biundo J, Quinet RJ et al. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med. 1985; 145:446-8. http://www.ncbi.nlm.nih.gov/pubmed/3977514?dopt=AbstractPlus

116. Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus verapamil: possible additive competition at alpha-adrenergic receptors. N Engl J Med. 1985; 312:167-70. http://www.ncbi.nlm.nih.gov/pubmed/2981405?dopt=AbstractPlus

117. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981; 64:437-41. http://www.ncbi.nlm.nih.gov/pubmed/7196300?dopt=AbstractPlus

118. Ochs HR, Jancik B, Kumm D. Atrial fibrillation: effect of diltiazem and verapamil, with and without quinidine. Clin Pharmacol Ther. 1984; 35:264.

119. Lilly USA. Quinidine gluconate injection prescribing information. Indianapolis, IN; 2012 Feb 24.

120. Bar-El Y, Shimoni Z, Flatau E. Quinidine-induced lupus erythematosus. Am Heart J. 1986; 111:1209-10. http://www.ncbi.nlm.nih.gov/pubmed/3487241?dopt=AbstractPlus

121. Phillips RE, Looareesuwan S, White NJ et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. BMJ. 1986; 292:1319-21. http://www.ncbi.nlm.nih.gov/pubmed/3085830?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1340320&blobtype=pdf

122. Rudnitsky G, Miller KD, Padva T et al. Continuous-infusion quinidine gluconate for treating children with severe Plasmodium falciparum malaria. J Infect Dis. 1987; 155:1040-3. http://www.ncbi.nlm.nih.gov/pubmed/3549916?dopt=AbstractPlus

123. Malaria Branch, US Centers for Disease Control, Atlanta, GA: Personal communication.

124. Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med. 1989; 321:65-70. http://www.ncbi.nlm.nih.gov/pubmed/2659994?dopt=AbstractPlus

125. Anon. Treatment of severe Plasmodium falciparum malaria with quinidine gluconate: discontinuation of parenteral quinine from CDC drug service. MMWR Morb Mortal Wkly Rep. 1991; 40:240. http://www.ncbi.nlm.nih.gov/pubmed/1848916?dopt=AbstractPlus

126. Anon. Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC drug service. MMWR Recomm Rep. 1991; 40(RR-4):21-3. http://www.ncbi.nlm.nih.gov/pubmed/1850497?dopt=AbstractPlus

128. White NJ, Plorde JJ. Malaria. In: Wilson JD, Braunwald E, Isselbacher et al, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw Hill, Inc; 1991:782-8.

129. Van Lith RM, Appleby DH. Quinidine-nifedipine interaction. Drug Intell Clin Pharm. 1985; 19:829-31. http://www.ncbi.nlm.nih.gov/pubmed/4064916?dopt=AbstractPlus

130. World Health Organization Division of Control of Tropical Diseases. Severe and complicated malaria. Trans R Soc Trop Med Hyg. 1990; 84(Suppl 2):1-65.

131. Verapamil/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:759.

132. Nifedipine/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:606.

133. Procainamide/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:596.

134. Anon. Drugs for parasitic infections. Treat Guidel Med Lett. 2010; 8:e1-16. http://www.medletter.com

135. Farringer JA, McWay-Hess K, Clementi WA. Cimetidine–quinidine interaction. Clin Pharm. 1984; 3:81-3. http://www.ncbi.nlm.nih.gov/pubmed/6697678?dopt=AbstractPlus

136. Green JA, Clementi WA, Porter C et al. Nifedipine–quinidine interaction. Clin Pharm. 1983; 2:461-5. http://www.ncbi.nlm.nih.gov/pubmed/6627876?dopt=AbstractPlus

137. Munger MA, Jarvis RC, Nair R et al. Elucidation of the nifedipine–quinidine interaction. Clin Pharmacol Ther. 1989; 45:411-6. http://www.ncbi.nlm.nih.gov/pubmed/2702799?dopt=AbstractPlus

138. Hughes B, Dyer JE, Schwartz AB. Increased procainamide plasma concentrations caused by quinidine: a new drug interaction. Am Heart J. 1987; 114:908-9. http://www.ncbi.nlm.nih.gov/pubmed/3661379?dopt=AbstractPlus

139. Farringer JA, Green JA, O’Rourke RA et al. Nifedipine-induced alterations in serum quinidine concentrations. Am Heart J. 1984; 108:1570-2. http://www.ncbi.nlm.nih.gov/pubmed/6507260?dopt=AbstractPlus

140. Cimetidine/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:604.

141. Wyler DJ. Malaria: overview and update. Clin Infect Dis. 1993; 16:449-58. http://www.ncbi.nlm.nih.gov/pubmed/8513046?dopt=AbstractPlus

142. Centers for Disease Control and Prevention. Availability of parenteral quinidine gluconate for treatment of severe or complicated malaria. MMWR Morb Mortal Wkly Rep. 1996; 45:494. http://www.ncbi.nlm.nih.gov/pubmed/8628210?dopt=AbstractPlus

143. Centers for Disease Control and Prevention. CDC treatment guidelines: Treatment of malaria (guidelines for clinicians). 2013 Jul. From the CDC website. Accessed 2013 Sep 27. http://www.cdc.gov/malaria

144. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States (based on drugs currently available for use in the United States–updated July 1, 2013). From the CDC website. Accessed 2013 Sep 27. http://www.cdc.gov/malaria

145. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation. 1991; 84:1977-83. http://www.ncbi.nlm.nih.gov/pubmed/1834365?dopt=AbstractPlus

146. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993; 270:1589-95. http://www.ncbi.nlm.nih.gov/pubmed/8371471?dopt=AbstractPlus

147. Pratt CM, Moye L. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development. J Clin Pharmacol. 1990; 30:967-74. http://www.ncbi.nlm.nih.gov/pubmed/2122983?dopt=AbstractPlus

148. Rosenthal PJ, Petersen C, Geertsma FR et al. Availability of intravenous quinidine for falciparum malaria. N Engl J Med. 1996; 235:138.

149. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation. 1990; 82:1106-16. http://www.ncbi.nlm.nih.gov/pubmed/2144796?dopt=AbstractPlus

153. Anon. Notice to readers: Availability and use of parenteral quinidine gluconate for severe or complicated malaria. MMWR Morb Mortal Wkly Rep.2000;49:1138-40.

154. Humar A, Sharma S, Zoutman D et al. Fatal falciparum malaria in Canadian travellers. CMAJ. 1997; 156:1165-7. http://www.ncbi.nlm.nih.gov/pubmed/9141989?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1227244&blobtype=pdf

156. Hansten PD, Horn JR eds. Drug Interactions. St. Louis MO: Facts and Comparisons; 2001 Apr: 673a.

157. Min DI, Ku Y, Geraets DR et al. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol. 1996; 36:469-76. http://www.ncbi.nlm.nih.gov/pubmed/8739026?dopt=AbstractPlus

159. Abbott Laboratories. Biaxin (clarithromycin) Filmtab tablets, XL Filmtab extended-release tablets, and granules for oral suspension prescribing information. North Chicago, IL; 2003 May.

161. World Health Organization (WHO). Guidelines for the treatment of malaria. 2nd edition. Geneva, Switzerland: World Health Organization; 2010. Updates may be available at WHO website. http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html

163. Teva Pharmaceuticals. Quinidine sulfate tablet, film coated, extended release prescribing information. Sellersville, PA; 2003 Jun.

164. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 18th ed. Philadelphia, PA: Elsevier Mosby: 2008.

165. Dubin A. Cardiac arrhythmias. In: Kliegman RM, Behrman RE, Jenson HB, eds. Kliegman: Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2007.

166. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. 1206-1209.

167. Watson Laboratories. Quinidine sulfate tablet USP prescribing information. Corona, CA; 2005 Jun.

168. Watson Laboratories. Quinidine gluconate tablet, extended-release prescribing information. Corona, CA; 2005 Jun.

169. Mutual Pharmaceutical. Quinidine gluconate tablet, extended-release prescribing information. Philadelphia, PA; 2004 Jan.

170. Sandoz. Quinidine sulfate tablet prescribing information. Princeton, NJ; 2008 Nov.

171. Centers for Disease Control and Prevention. Notice to readers: new medication for severe malaria available under an investigational new drug protocol. MMWR Morb Mortal Wkly Rep. 2007; 56:769-70.

172. Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States. From CDC website. Accessed 2014 Jun 2. http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html

174. Avanir Pharmaceuticals, Inc. Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules prescribing information. Aliso Viejo, CA; 2013 Dec.

300. Page RL, Joglar JA, Caldwell MA et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67:e27-e115.

301. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1-76. http://www.ncbi.nlm.nih.gov/pubmed/24685669?dopt=AbstractPlus

b. AHFS drug information 2017. McEvoy GK, ed. Quinidine Gluconate, Quinidine Quinidine Sulfate. Bethesda, MD: American Society of Health-System Pharmacists; 2017.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:998-9.

The content of Holevn is solely for the purpose of providing information about Thuốc Quinidine Sulfate  and is not intended to be a substitute for professional medical advice, diagnosis or treatment. Please contact your nearest doctor or clinic, hospital for advice. We do not accept liability if the patient arbitrarily uses the drug without following a doctor’s prescription.

Reference from: https://www.drugs.com/monograph/quinidine-sulfate.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here